Abbott Laboratories Stock Performance
Abbott Laboratories shares traded at $104.48, reflecting a modest daily gain of 0.47% per SID market data. Over the trailing one-month period, ABT posted a slight increase of 0.62%, while the three-month and one-year returns showed declines of 8.49% and 16.23%, respectively, underscoring sustained downward pressure over longer timeframes. The stock currently sits above both its 50-day moving average of $103.88 and its 200-day moving average of $101.57, according to Massive/Polygon technical data, suggesting near-term price stabilization following the broader pullback. The 14-day relative strength index stands at 53.6, placing ABT in neutral territory between overbought and oversold conditions. Average daily trading volume registers at approximately 8.88 million shares, while the company carries a market capitalization of $202.45 billion. ABT's beta of 0.751 indicates lower volatility relative to the broader market, consistent with its defensive healthcare sector positioning.
Abbott Laboratories Valuation Analysis
Abbott Laboratories trades at a price-to-earnings ratio of 31.15, per SID market data, reflecting a premium valuation relative to the broader healthcare sector. The company's price-to-book ratio stands at 3.90, according to SEC filings, indicating the market prices ABT shares at nearly four times the company's book value per share. The PEG ratio registers at negative 0.58, a metric that in this context reflects challenges in reconciling the current earnings multiple with forward growth expectations. Abbott currently offers a dividend yield of 2.06%, providing income-oriented investors with a steady return component. The combination of a relatively elevated P/E ratio and a negative PEG ratio suggests that the market continues to assign a premium to Abbott's diversified healthcare portfolio, though the valuation may face scrutiny if earnings growth does not accelerate. The $202.45 billion market capitalization positions Abbott among the largest healthcare companies globally.
Smart Money Activity for ABT
Abbott Laboratories registers a composite smart money score of 48 out of 100, signaling a neutral stance among sophisticated market participants, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating robust confidence from large asset managers as reflected in 13F institutional filings. In contrast, insider activity scores 9.3 out of 25, with SEC Form 4 filings revealing 16 insider transactions over the past 90 days, comprising 7 purchases and 9 sales. The slight tilt toward insider selling contributes to the subdued insider sentiment reading. Dark pool activity scores 8.5 out of 25, suggesting below-average levels of off-exchange institutional accumulation. Congressional trading activity registers at 5.3 out of 25, reflecting minimal notable legislative trading interest in ABT shares during the observed period. The divergence between strong institutional holdings and weaker insider and dark pool signals creates a mixed overall smart money profile, with large-scale institutional investors maintaining positions while insiders modestly reduce exposure.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated consistent earnings execution across recent quarters, per company earnings reports. In the most recent reported quarter, Abbott delivered earnings per share of $1.42, matching the consensus analyst estimate exactly with zero surprise. The prior quarter showed EPS of $1.31, exceeding the $1.28 estimate by $0.03, representing a positive surprise of approximately 2.3%. Before that, Abbott posted EPS of $1.15 against a $1.14 estimate, delivering a $0.01 beat. This sequential earnings progression from $1.15 to $1.31 to $1.42 illustrates a steady upward trajectory in quarterly profitability. Looking ahead, analyst estimates project EPS of $1.42 for the upcoming quarter, identical to the most recently reported figure. The pattern of meeting or modestly exceeding expectations across consecutive quarters reflects Abbott's operational consistency, though the absence of meaningful upside surprises may limit positive earnings-driven catalysts in the near term.
Wall Street Analyst Ratings for ABT
Wall Street coverage of Abbott Laboratories presents a predominantly constructive outlook, though one notable downgrade has emerged, per SID consensus data. On October 27, 2026, Argus Research downgraded ABT from Buy to Hold, representing the most significant recent rating change, according to Wall Street analyst reports. However, the remaining recent coverage reaffirmed positive stances: Wells Fargo maintained its Overweight rating on October 23, while both JP Morgan and Baird reiterated Overweight and Outperform ratings, respectively, on October 22. TD Cowen also maintained its Buy rating on October 22. The concentration of four maintained positive ratings against one downgrade suggests the broader analyst community remains favorable toward Abbott's fundamentals, even as Argus Research's shift to Hold introduces a more cautious perspective. The Argus downgrade is particularly notable given its timing immediately following Abbott's earnings report, where the company matched but did not exceed the $1.42 consensus EPS estimate, potentially reflecting concerns about growth momentum at current valuation levels.